drugset / Trial / NCT03423355

Dapagliflozin Effect on Erythropoiesis and Physical Fitness

NCT03423355

Phase 4 Withdrawn University Hospital Tuebingen
RandomizedParallel-groupTriple-blindTreatment

Summary

Dapagliflozin effect on erythropoiesis and physical fitness in patients with type 2 diabetes - a randomized, partly double-blinded, controlled, three armed, parallel group, exploratory study

Timeline

Start
2021-09
Primary completion
2023-03
Completion
2023-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Dapagliflozin Small molecule 10 mg Oral
Subject Hydrochlorothiazide Unknown 25 mg Oral